Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available.
IRLAB Therapeutics AB announced an increase in the number of shares and votes due to a rights issue resolved by the Board of Directors. As of August 29, 2025, the total number of shares is 84,938,020, with an equal number of votes, indicating a strategic move to potentially enhance capital and shareholder value.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics is a Swedish company that discovers and develops transformative treatments for all stages of Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research, the company focuses on treatments like Mesdopetam for levodopa-induced dyskinesias, Pirepemat for reducing fall frequency, and IRL757 for apathy in neurodegenerative disorders. Their research is driven by a proprietary systems biology-based platform, and they are listed on Nasdaq Stockholm.
Average Trading Volume: 129,704
Technical Sentiment Signal: Sell
Current Market Cap: SEK262.2M
For a thorough assessment of IRLAB.A stock, go to TipRanks’ Stock Analysis page.